Tag : ALECTINIB

CONFERENCE UPDATE

Resectable NSCLC in transition: Integrating immunotherapy and targeted approaches
The landscape of early-stage non-small cell lung cancer is undergoing a rapid transformation. Once defined by the modest survival gains of adjuvant chemotherapy, treatment strategies now extend to immunotherapy and targeted therapies in both adjuvant and neoadjuvant settings.
CONFERENCE UPDATE

Alectinib prolongs OS and shows durable response in previously untreated advanced ALK+ NSCLC: Final OS analysis from the phase 3 ALEX study
The ALEX study's final analysis shows that first-line alectinib significantly improves overall survival and duration of response in untreated advanced ALK-positive non-small cell lung cancer (NSCLC) compared to crizotinib, reinforcing alectinib as the standard of care for these patients.

Professor Mok Shu Kam Tony

Chairman, Department of Clinical Oncology, The Chinese University of Hong Kong